U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07940023) titled 'Bispecific PSMAxCD3 Antibody CC-1 Applied Subcutaneously in Patients With Castration Resistant Prostate Carcinoma' on Nov. 04.
Brief Summary: This trial is a phase I trial in patients with metastasized castration resistant prostate cancer (mCRPC) after failure of at least third-line therapy aiming to evaluate safety and efficacy of CC-1, a bispecific antibody (bsAb) with PSMAxCD3 specificity. CC-1 binds to human prostate-specific membrane antigen (PSMA) on prostate cancer cells as well as to tumor vessels of CRPC, thereby allowing for a dual mode of anti-cancer action. CC-1 was developed in a novel format which not only prolongs ser...